--- title: "Bunsen now runs 80% of Schrödinger's own modeling jobs, and November 4 shows if customers pay for it" description: "Schrödinger's Bunsen agent now runs roughly 80 percent of the computational jobs on the company's own cluster, a reversal for a CEO who called AI drug discovery nonsense in 2024. With full launch due by year-end and Q3 results on Nov. 4, the throughput-licensing model is about to be tested on customers, not just insiders." publisher: "The Inference" section: "Health" published: 2026-10-27T16:28:02.168Z modified: 2026-10-27T16:28:02.168Z canonical: https://theinference.org/article/bunsen-now-runs-80-of-schrodinger-s-own-modeling-jobs-and-november-4-shows-if-customers-pay-for-it language: en keywords: "Schrodinger, Bunsen, Ramy Farid, Robert Abel, AI Drug Discovery, Computational Chemistry" --- # Bunsen now runs 80% of Schrödinger's own modeling jobs, and November 4 shows if customers pay for it > Schrödinger's Bunsen agent now runs roughly 80 percent of the computational jobs on the company's own cluster, a reversal for a CEO who called AI drug discovery nonsense in 2024. With full launch due by year-end and Q3 results on Nov. 4, the throughput-licensing model is about to be tested on customers, not just insiders. For two years, [Schrödinger](https://theinference.org/markets/companies/schrodinger) ran its own drug-design calculations through an AI agent that nobody had approved. Free energy estimates, molecular dynamics runs, quantum calculations: by company CSO Robert Abel's own count, [roughly 80 percent of the computational modeling jobs on the company's HPC cluster](https://eternalsearch.net/news/261011012) are now executed by Bunsen, an agentic AI co-scientist the company released to early-access customers in late July 2026 [1][2]. What that means for the drug-discovery workforce, and for Schrödinger's own revenue model, is the calculation now being tested [1][2]. ## The scientist still signs off on the plan The design is unusual for an AI tool: the language model inside Bunsen does not predict any molecular property itself. It chooses among Schrödinger's validated physics-based methods, which produce the numbers, and lays out a plan a scientist must approve before a campaign runs without continuous supervision [2]. Abel says the setup keeps an external check the model cannot fake, because the simulation itself flags results that fail to converge on physically consistent answers. He points to MYCIN, the Stanford expert system of the 1970s that scored well on infection diagnosis yet never entered clinical practice, as the contrast case [1][2]. The agent watches for errors the simulation can catch; it still cannot judge whether it understood the scientific question [1][2]. ## The skeptic who ran the numbers [Ramy Farid](https://theinference.org/markets/people/ramy-farid), the company's chief executive, called AI-driven drug discovery "nonsense" in [a 2024 STAT interview](https://www.biopharmatrend.com/interviews/interview-with-robert-abel-from-schrodinger/) [2][5]. [At Bunsen's launch in July](https://ir.schrodinger.com/press-releases/news-details/2026/Schrdinger-Introduces-Bunsen-an-AI-Co-Scientist-for-Molecular-Discovery/default.aspx) he reversed himself, saying he had been highly skeptical and could not be happier to have been wrong. That reversal matters commercially, because Schrödinger licenses its software on a throughput basis, so wider use by customers converts directly into revenue [2][5]. Abel said formal licensing terms are not yet announced, and the company plans full commercial release by the end of 2026 on infrastructure from [NVIDIA](https://theinference.org/markets/companies/nvidia) and Google Cloud [1][5]. ## What the Nov. 4 print will test The financial stakes are visible in the transition already underway. Schrödinger reported software revenue of about $200 million for 2025, with software annual contract value of $198 million, and [has told investors it wants roughly 75 percent of contracts on hosted delivery](https://finance.yahoo.com/sectors/healthcare/articles/schrodinger-conference-sdgr-targets-hosted-081018124.html) within three years, from about 25 percent, a shift that makes revenue recognition more ratable and pushes reported revenue down before it recovers [3]. [Deferred revenue, the pool of contracted work not yet recognized](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001490978), declined year over year in every quarter of 2026 through June, down about 20 percent in the June quarter, as those hosted conversions took effect [6]. Abel noted that computational chemists typically support three or four projects at once, so the agent's pitch is to lift that ceiling rather than to replace the scientist [2]. ## The counterargument: speed, proven quality not yet Skeptics will note, correctly, that Abel conceded no experiment comparing drug programs with and without the agent would be affordable to run. The claim that Bunsen improves decisions, not only their speed, rests on inference rather than a controlled trial [2]. [Third quarter 2026 results, due November 4](https://www.businesswire.com/news/home/20261021075948/en/Schrdinger-to-Announce-Third-Quarter-2026-Financial-Results-on-November-4) after market close, will show whether Bunsen's internal adoption is showing up as customer throughput yet [4]. The number that settles the agent's value will not be the adoption percentage. It will be whether customers pay for more campaigns once their own chemists stop being the bottleneck. ## Takeaway Schrödinger's Bunsen agent now executes roughly 80% of the computational jobs on the company's own HPC cluster, while a scientist approves each campaign's plan. Full commercial launch is due by year-end on NVIDIA and Google Cloud infrastructure, and Nov. 4 Q3 results will test whether customer throughput turns internal adoption into revenue. ## Sources 1. [Eternal Search, Schrödinger says its Bunsen agent now handles 80% of the company's computational drug discovery tasks, 11 October 2026](https://eternalsearch.net/news/261011012) 2. [BiopharmaTrend, interview with Robert Abel from Schrödinger, October 2026](https://www.biopharmatrend.com/interviews/interview-with-robert-abel-from-schrodinger/) 3. [MarketBeat via Yahoo Finance, Schrodinger Conference: SDGR Targets Hosted Shift, Platform Adoption, EBITDA Profitability in 3 Years, 22 March 2026](https://finance.yahoo.com/sectors/healthcare/articles/schrodinger-conference-sdgr-targets-hosted-081018124.html) 4. [Business Wire, Schrödinger to Announce Third Quarter 2026 Financial Results on November 4, 21 October 2026](https://www.businesswire.com/news/home/20261021075948/en/Schrdinger-to-Announce-Third-Quarter-2026-Financial-Results-on-November-4) 5. [Schrödinger press release, Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery, 27 July 2026](https://ir.schrodinger.com/press-releases/news-details/2026/Schrdinger-Introduces-Bunsen-an-AI-Co-Scientist-for-Molecular-Discovery/default.aspx) 6. [Schrödinger quarterly deferred revenue from SEC filings, retrieved 27 October 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001490978) --- Bunsen now runs 80% of Schrödinger's own modeling jobs, and November 4 shows if customers pay for it — The Inference. Canonical: https://theinference.org/article/bunsen-now-runs-80-of-schrodinger-s-own-modeling-jobs-and-november-4-shows-if-customers-pay-for-it